Text Size

Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01210209
First received: September 25, 2010
Last updated: September 27, 2010
Last verified: September 2010
History of Changes
  Purpose

RATIONALE: Studying samples of blood in the laboratory from patients with cancer and their relatives may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples collected from patients with Ewing sarcoma and their relatives.


Condition Intervention
Sarcoma
 Other: laboratory biomarker analysis

Study Type: Observational
Official Title: GENEWING - A Genome Wide Association Study in Ewing Sarcoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Identification and characterization of susceptibility genes in patients with Ewing sarcoma [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: September 2009
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To identify and characterize a genetic susceptibility factor to Ewing's sarcoma by performing a Genome-Wide Association Study with as many as possible Ewing sarcoma patients.

OUTLINE: This is a multicenter study.

Blood samples are collected from patients and their relatives. Blood DNA samples are analyzed for susceptibility genes of Ewing Sarcoma.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Patients with Ewing sarcoma
  • Relatives of Ewing sarcoma patients

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01210209

Locations
France
Institut Curie Hopital Recruiting
Paris, France, 75005
Contact: Contact Person     33-1-5624-6679     olivier.delattre@curie.fr    
Sponsors and Collaborators
Institut Curie
Investigators
Principal Investigator: Olivier Delattre, MD Institut Curie
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT01210209     History of Changes
Other Study ID Numbers: CDR0000683940, CLCC-IC-2009-02, 2009-A00558-49, EU-21064
Study First Received: September 25, 2010
Last Updated: September 27, 2010
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
Ewing sarcoma
Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET)

Additional relevant MeSH terms:
Sarcoma, Ewing's
Sarcoma
Neuroectodermal Tumors, Primitive, Peripheral
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
 Neoplasms
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on May 16, 2013